Healing Haven Ancillary Services Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 30821 Barrington St, Madison Hts, MI 48071 Phone: 248-965-3916 |
Mrs. Rasa Terese Poorman, OTR CHT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1432 E 12 Mile Rd, Madison Hts, MI 48071 Phone: 248-543-4886 Fax: 248-543-4886 |
Healing Haven, Llc Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 30821 Barrington St, Madison Hts, MI 48071 Phone: 248-965-3916 Fax: 248-331-9919 |
Amanda Claire Alfery, OT Occupational Therapist Medicare: Medicare Enrolled Practice Location: 30821 Barrington St, Madison Hts, MI 48071 Phone: 248-965-3916 Fax: 248-331-9919 |
News Archive
Researchers in Australia have conducted a study showing that commonly used nonnutritive sweeteners can promote the spread of antibiotic-resistant genes in the intestine.
In the first combat-zone study of its kind, a research team led by Michigan State University found that soldiers with a positive outlook in the most traumatic situations were less likely to suffer health problems such as anxiety and depression.
Merck & Co. Inc., (operating in the United Kingdom as MSD) and Avecia Investments Limited today announced that they have entered into a definitive agreement by which Merck will acquire the biologics business of the Avecia group through a Merck affiliate (Merck Sharp & Dohme (Holdings) Limited or "MSD"). Avecia Biologics is a contract manufacturing organization with specific expertise in microbial-derived biologics. Financial details of the transaction were not disclosed.
At the start of the COVID-19 pandemic, stay-at-home orders and other restrictions drastically affected how people lived and worked, resulting in social isolation and economic instability. Now, researchers show that some people turned to a variety of drugs for relief. Using wastewater analysis, the team identified a spike in consumption of easily abused prescription opioids and anti-anxiety sedatives, while some illicit drug use plummeted, between March and June 2020.
Bioheart, Inc., announced today plans for establishing two Centers of Excellence in the Middle East to provide its cell therapy procedures to patients suffering from congestive heart failure and peripheral arterial disease. Dr. Karl E. Groth, Chairman and CEO, and Peggy A. Farley, Chief Operating and Financial Officer, are now in that region holding discussions and performing site inspections.
› Verified 1 days ago